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Nearly 1 billion people worldwide are affected by hypertension. 
Despite current pharmacological approaches to control blood pres-
sure, this condition remains one of the most common causes of heart 
failure, kidney disease and stroke1. Endothelial dysfunction is associ-
ated with hypertension, and is an early event contributing to vascular 
tone dysregulation2–4.
Endothelium-released nitric oxide (NO) is of critical importance 
for the maintenance of normal blood pressure5–7. Sphingolipids, par-
ticularly sphingosine-1-phosphate (S1P), have emerged as a class of 
bioactive lipids with important functions in cardiovascular homeos-
tasis, including blood pressure control. Acting through G protein– 
coupled S1P receptors, S1P regulates arterial tone. At low concentra-
tions, S1P induces vasodilation through the receptors S1P1 and S1P3 
on endothelial cells, via activation of endothelial nitric oxide synthase 
(eNOS) and NO8,9. At higher concentrations, S1P causes vasocon-
striction through S1P2 and S1P3 activation on vascular smooth muscle 
cells (VSMCs)10,11.
The endothelium is not only a target of S1P action but also an 
important source of plasma S1P12; red blood cells are the major 
source12–14. Stimulated by blood flow, endothelial-derived S1P is 
transported out of the cell through the spinster-2 transporter15; S1P 
activates S1P1 on the cell surface in an autocrine fashion to induce 
barrier-protective effects16 and control vascular tone. Moreover, a 
recent study reported that S1P1 is required for eNOS-activation in 
response to shear stress17. These findings suggest that S1P levels 
within the vascular wall must be tightly controlled to maintain vascular 
homeostasis. How S1P production within the vascular wall is 
regulated and the roles of S1P in physiological and hypertensive con-
ditions are still unknown.
Sphingolipids are produced by the de novo biosynthetic pathway 
in the endoplasmic reticulum (ER). The rate-limiting enzyme, serine 
palmitoyltransferase (SPT), catalyzes the condensation of serine and 
palmitoyl-coenzyme A18,19. Because sphingolipids are involved in 
many pathophysiological processes, the expression and regulation 
of SPT has attracted much attention. A recently discovered major 
regulatory system for SPT involves ORMDL proteins20,21, which 
have been suggested to be involved in childhood asthma on the basis 
of genome-wide association studies22. Here we identify Nogo-B, 
a membrane protein of the ER and part of the reticulon-4 (Rtn4) 
protein family, as a key negative regulator of de novo sphingolipid 
biosynthesis and reveal the importance of local sphingolipid homeo-
stasis in preserving endothelial function and blood pressure.
RESULTS
Nogo-B regulates blood pressure through an eNOS pathway
Nogo-B belongs to the Rtn4 family of proteins, which comprises 
three major splice isoforms: Nogo-A and Nogo-C are abundantly 
expressed in the central nervous system, and Nogo-C23,24 is also found 
in skeletal muscle; Nogo-B is expressed highly but not exclusively in 
endothelial cells and VSMCs of blood vessels, including mesenteric 
arteries25 (Fig. 1a). Mice lacking the Nogo-A and Nogo-B isoforms 
(hereafter referred to as Nogo-A/B-deficient mice)24, were markedly 
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Nogo-B regulates endothelial sphingolipid homeostasis  
to control vascular function and blood pressure
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Endothelial dysfunction is a critical factor in many cardiovascular diseases, including hypertension. Although lipid signaling has 
been implicated in endothelial dysfunction and cardiovascular disease, specific molecular mechanisms are poorly understood. Here 
we report that Nogo-B, a membrane protein of the endoplasmic reticulum, regulates endothelial sphingolipid biosynthesis with direct 
effects on vascular function and blood pressure. Nogo-B inhibits serine palmitoyltransferase, the rate-limiting enzyme of the de novo 
sphingolipid biosynthetic pathway, thereby controlling production of endothelial sphingosine 1-phosphate and autocrine, G protein–
coupled receptor–dependent signaling by this metabolite. Mice lacking Nogo-B either systemically or specifically in endothelial cells 
are hypotensive, resistant to angiotensin II–induced hypertension and have preserved endothelial function and nitric oxide release. 
In mice that lack Nogo-B, pharmacological inhibition of serine palmitoyltransferase with myriocin reinstates endothelial dysfunction 
and angiotensin II–induced hypertension. Our study identifies Nogo-B as a key inhibitor of local sphingolipid synthesis and shows 
that autocrine sphingolipid signaling within the endothelium is critical for vascular function and blood pressure homeostasis.
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
A r t i c l e s
nAture medicine	 VOLUME 21 | NUMBER 9 | SEPTEMBER 2015 1029
hypotensive compared to wild-type (WT) control mice (Fig. 1b), 
with no significant increase in heart rate. Consistent with their lower 
blood pressure, the thickness/radius ratio of the mesenteric arteries 
of Nogo-A/B-deficient mice was significantly reduced as compared 
with WT mice (Fig. 1b). To assess the role of Nogo-B in VSMC func-
tion, we evaluated vasoconstriction in the mesenteric arteries of WT 
and Nogo-A/B-deficient mice in response to increasing concentra-
tions of the adrenergic α1 receptor agonist phenylephrine (PE), the 
thromboxane A2 receptor agonist U-46619 and S1P (S1P2 and S1P3 
receptor ligand). We found no differences between the two groups 
of mice in the vasoconstrictive responses of the mesenteric arteries 
(Supplementary Fig. 1a–c and Supplementary Data 1), suggesting 
that hypotension in Nogo-A/B-deficient mice cannot be ascribed 
to an impaired contractility of resistance vessels. Accordingly, we 
focused on the role of Nogo-B in the endothelium.
Given the important role of NO as an endogenous endothelial-
derived vasodilator, we assessed the activation of eNOS. Nogo-A/B-
deficient aortas showed a marked increase of eNOS phosphorylated 
at Ser1176 (p-Ser1176-eNOS) as compared to WT aortas, as assessed 
by western blot and en face immunofluorescence staining (Fig. 1c,d), 
whereas total eNOS (Fig. 1c and Supplementary Fig. 1d) and neu-
ronal NOS (nNOS) (Supplementary Fig. 1e) levels were unchanged. 
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Figure 1 Loss of Nogo-A and Nogo-B upregulates  
eNOS-NO and flow-mediated vasodilation, leading to  
hypotension. (a) Immunohistochemical staining of  
Nogo-B in WT and Nogo-A/B-deficient (inset) mesenteric  
arteries. (b) Left, SBP, diastolic blood pressure (DBP)  
and mean blood pressure (MBP) in WT (n = 16) and  
Nogo-A/B-deficient (n = 14) mice. Right, morphometric  
analysis of Verhoeff–Van Gieson–stained mesenteric  
arteries from WT (n = 10) and Nogo-A/B-deficient (n = 8)  
mice. T/R, ratio of vessel thickness to radius. Error bars,  
mean ± s.e.m. *P < 0.05 (Nogo-A/B-deficient vs. WT T/R ratio);  
***P < 0.001, unpaired t-test. (c) Western blot analysis of  
p-Ser1176-eNOS and eNOS expression in thoracic aortas.  
Numbers represent the p-Ser1176-eNOS/eNOS ratio as determined  
by densitometric analysis. β-actin was used as a loading control. (d) En face staining of WT and Nogo-A/B-deficient aortas for eNOS, p-Ser1176-eNOS 
and vascular endothelial (VE)-cadherin. (e) Top, plasma levels of nitrite (NOx) in WT and Nogo-A/B-deficient mice (n = 9 mice per group); bottom, basal 
(Bas) and A23187-stimulated cGMP concentrations in aortas from WT and Nogo-A/B-deficient mice (n = 5 mice per group). Error bars, mean ± s.e.m. 
*P < 0.05; **P < 0.01, unpaired t-test (top) or one-way ANOVA (bottom). (f) Left, l-NAME–induced decrease in luminal diameter versus baseline  
in mesenteric arteries from WT (n = 9) and Nogo-A/B-deficient (n = 7) mice. Right, Ach concentration-response curves with or without l-NAME  
treatment in mesenteric arteries from WT (n = 8) and Nogo-A/B-deficient (n = 5) mice. Error bars, mean ± s.e.m. **P < 0.01; ***P < 0.001,  
unpaired t-test (left) or two-way ANOVA followed by Bonferroni’s post hoc test (right). (g) Ach concentration-response curves in the presence or absence 
of indomethacin (indom) in mesenteric arteries from WT (n = 11) and Nogo-A/B-deficient (n = 6) mice. Error bars, mean ± s.e.m. ***P < 0.001,  
two-way ANOVA. (h) Ach concentration-response curves after incubation with indomethacin and l-NAME in mesenteric arteries from WT and  
Nogo-A/B deficient mice (n = 5 per group). (i) Left, flow-induced vasodilation without and with l-NAME treatment in mesenteric arteries from  
WT (n = 6) and Nogo-A/B-deficient (n = 7) mice. Right, myogenic tone without and with l-NAME treatment in mesenteric arteries from WT (n = 5)  
and Nogo-A/B-deficient (n = 8) mice. P, pressure. Error bars, mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001, two-way ANOVA (right) followed  
by Bonferroni’s post hoc test (left). (j) Left, l-NAME–induced decrease, compared to baseline, in luminal diameter in carotid arteries from WT and  
Nogo-A/B-deficient mice (n = 6 mice per group); middle, Ach concentration-response curves without or with l-NAME (n = 6 per group); right,  
flow-induced vasodilation without or with l-NAME (n = 6 per group). Error bars, mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001,  
unpaired t-test (left) or two-way ANOVA followed by Bonferroni’s post hoc test (middle and right).
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These findings were supported by higher plasma levels of nitrites 
(a breakdown product of NO) and a robust increase in basal and stim-
ulated cyclic guanosine monophosphate (cGMP) levels in Nogo-A/B-
deficient aortas as compared to WT (Fig. 1e). To confirm these data, 
we evaluated basal and acetylcholine (Ach)-stimulated eNOS-derived 
NO in mesenteric arteries mounted in a pressure myograph. We used 
l-NG-nitroarginine methyl ester (l-NAME) and indomethacin as 
pharmacological inhibitors of eNOS and cyclooxygenase, respec-
tively, to dissect the role of NO, prostacyclin and endothelium-derived 
hyperpolarizing factor (EDHF) in Ach-induced vasodilation. Basal 
and stimulated NO production were markedly increased in mesenteric 
arteries from Nogo-A/B-deficient mice as compared to controls 
(Fig. 1f). In contrast, the contribution of prostacyclin to vasodila-
tion was significantly smaller in Nogo-A/B-deficient than in WT 
mesenteric arteries (Fig. 1g). EDHF had an equal role in Nogo-A/B-
deficient and WT mesenteric arteries, leaving the net response to Ach 
unchanged (Fig. 1h). These results were not surprising, given the 
compensatory cross-talk between the NO and cyclooxygenase (COX) 
pathways26. These data suggest that endothelial Nogo-B negatively 
regulates eNOS-derived NO production.
Flow-induced dilation and pressure-induced constriction (myo-
genic tone) are fundamental mechanisms controlling vascular tone, 
with flow-induced dilation opposing myogenic tone27,28. NO is 
the major mediator of flow-induced vasorelaxation. In Nogo-A/B-
deficient mesenteric arteries, vasodilation in response to a stepwise 
increase in flow was significantly enhanced compared to WT arteries 
(Fig. 1i). l-NAME treatment blunted flow-induced vasorelaxation in 
both groups. Conversely, the development of myogenic tone induced 
by a stepwise increase in pressure was substantially reduced in WT 
mesenteric arteries in the absence of Nogo-B; l-NAME treatment 
potentiated the myogenic response to pressure equally in the two 
groups (Fig. 1i). Loss of Nogo-B led to hyperactivation of eNOS and 
increased flow-induced vasodilation in carotid arteries (Fig. 1j). 
Together, these findings suggest that endothelial Nogo-B has an 
important role in the regulation of vessel tone via the endothelial NO 
pathway, such that loss of Nogo-B alters systemic blood pressure.
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Figure 2 Nogo-B is a negative regulator of sphingolipid  
de novo biosynthesis. (a,b) Total ceramide levels (a)  
and individual sphingolipid species (b) in MLECs from  
WT and Nogo-A/B-deficient mice, measured by LC-MS.  
n = 7 independent isolations of MLEC per group. dhSph,  
dihydrosphingosine; Sph, sphingosine. (c) S1P  
concentrations in the culture medium of WT and  
Nogo-A/B-deficient MLECs treated with vehicle or  
myriocin (n = 6 replicates from 3 independent MLEC  
isolations per group). (d) Left, plasma S1P levels in  
WT and Nogo-A/B-deficient mice (three independent  
analyses, #1–#3); right, the same data expressed as fold increase compared to WT levels (WT n = 6; Nogo-A/B-deficient, n = 7 mice per group). 
(e) Western blot analysis to detect SPTLC1; ORMDL1, ORMDL2 and ORMDL3; calnexin and HA-tagged Nogo-B in whole cell lysates (WCL) or 
immunoprecipitates with anti-HA agarose (IP: HA) of HEK293T cells transfected with SPTLC1 and HA-tagged Nogo-B or SPTLC1 alone as a control.  
HC IgG, heavy chain immunoglobulin; LC IgG, light chain immunoglobulin. (f) Nogo-B and SPTLC1 coimmunoprecipitation in mouse lung lysates,  
as assessed by western blot analysis. HEK293T cells overexpressing SPTLC1 were used as a positive control. (g) Immunofluorescence staining of  
COS7 cells transfected with vectors expressing SPTLC1 and HA-tagged Nogo-B. Bottom, magnified view of outlined area (top). (h) SPT activity, 
measured using [3H]serine as substrate followed by TLC separation of sphinganine, in WT and Nogo-A/B-deficient MLECs and HUVECs transfected 
with Nogo-B siRNA (si-Nogo-B) or control siRNA (si-CTR) and cultured for 72 h (left, n = 8 replicates derived from 3 independent experiments per 
group); and in WT and Nogo-A/B-deficient MLECs treated with lentivirus expressing GFP or HA-tagged Nogo-B (right, n = 5, n = 7 and n = 7 replicates, 
respectively, derived from 3 independent experiments). Top, western blotting for Nogo-B in HUVECs (left) and in MLECs (right). (i,j) SPT activity in 
lung microsomes from WT and Nogo-A/B-deficient mice (n = 11 replicates derived from 6 mice per group) (i) and in HUVECs transfected with Nogo-B 
receptor siRNA (si-NgBR) or control siRNA (si-CTR) and cultured for 72 h (n = 9 replicates derived from 3 independent experiments) (j). The western 
blot in j shows levels of NgBR and HSP90 in HUVECs. Data are expressed as mean ± s.e.m. *P < 0.05; **P < 0.01 compared to WT; ##P < 0.01 
compared to control (si-CTR) HUVECs (unpaired t-test) (a–d,h–j).
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Nogo-B negatively regulates sphingolipid synthesis through SPT
Considering the subcellular localization of Nogo-B and eNOS in 
the tubular ER and the Golgi, respectively, we reasoned that a direct 
interaction between the two proteins is unlikely. Although it has been 
suggested that the Rtn4 protein regulates channels responsible for 
store-operated calcium entry in cultured fibroblasts29, the equivocal 
role of these channels in VSMC contractility and the normal contrac-
tile responses of Nogo-A/B-deficient mesenteric arteries in response 
to a variety of vasoconstrictors suggest that Nogo-B is unlikely to 
regulate calcium signaling in VSMCs. Moreover, Nogo-B does not 
alter triglyceride synthesis29. Given the importance of sphingolipids in 
controlling blood vessel function8,9,17,30, we hypothesized that Nogo-
B regulates sphingolipid homeostasis.
Quantification of sphingolipid levels by liquid chromatography–
tandem mass spectrometry (LC-MS/MS) showed a consistent increase 
(~30%) in total ceramide levels in the absence of Nogo-B in primary 
endothelial cells isolated from mouse lung (MLECs) but not in VSMCs 
(Fig. 2a, Supplementary Fig. 2a,b and Supplementary Data 2). 
This may be due to differential contributions of the de novo sphingolipid 
pathway to sphingolipid levels in endothelial and smooth muscle cells 
(total ceramide levels were 1,417 ± 108 (s.e.m.) pmol mg−1 ml−1 in WT 
MLECs and 850 ± 46 (s.e.m.) pmol mg−1 ml−1 in WT VSMCs; Fig. 2a 
and Supplementary Fig. 2a). Quantification of sphingolipid species 
in endothelial cells showed that only specific ceramide species, includ-
ing cer-C18, cer-C20 and cer-C22, were significantly increased in the 
absence of Nogo-B (Fig. 2b), whereas the levels of cer-C16, cer-C24 and 
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(b) in WT and Nogo-A/B-deficient mice 1 d after treatment with myriocin (my, 0.3 mg per kg body weight (mg/kg) intraperitoneally (i.p.) or vehicle  
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(e) flow-induced vasodilation (left, n = 5 per group), myogenic tone (middle, n = 5 WT and n = 7 Nogo-A/B-deficient arteries) and PE-induced 
vasoconstriction (right, n = 6 WT and n = 8 Nogo-A/B-deficient arteries). (f) Mesenteric arteries from WT mice incubated with W146 and evaluated  
for S1P-induced relaxation (left; n = 4 per group), flow-induced vasodilation (middle; n = 5 per group) and myogenic tone (right; n = 5 per group).  
(g,h) Mesenteric arteries from WT and Nogo-A/B-deficient mice incubated with W146 or vehicle for 45 min and evaluated for decreased luminal 
diameter at baseline (g; left, representative trace; right, quantification; n = 9 WT and n = 6 Nogo-A/B-deficient arteries) and flow-induced vasodilation 
(h; left, n = 5 WT and n = 4 Nogo-A/B-deficient arteries) and myogenic tone (right, n = 5 WT and n = 4 Nogo-A/B-deficient arteries). (i) Vasodilation  
to S1P in mesenteric arteries from WT (n = 4) and Nogo-A/B-deficient (n = 5) mice treated with myriocin or vehicle. (j) Left, western blot analysis 
for S1P1 in MLECs from WT and Nogo-A/B-deficient mice. HSP90 was used as a loading control. n = 4 independent isolations of MLECs per group. 
The graph shows densitometric analysis of S1P1 expressed as a ratio to HSP90. Right, immunofluorescence staining of S1P1 in en face preparations 
of WT and Nogo-A/B-deficient aortas. Insets, magnified views. Data are expressed as mean ± s.e.m.; **P < 0.01; ***P < 0.001 compared to WT or 
as otherwise indicated (a–j); ###P < 0.001, Nogo-A/B-deficient + W146 vs. Nogo-A/B-deficient (h); †P < 0.001, myriocin vs. vehicle (i). Statistical 
significance was determined by unpaired t-test (a,g,j), one-way ANOVA (b,c) or two-way ANOVA followed by Bonferroni’s post hoc test (e,f,h,i).
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cer-C24:1 (the most abundant ceramide species, which  are involved 
in apoptosis31 and survival signaling32), were unchanged (Fig. 2b). 
Notably, the levels of sphingosine, a breakdown product of ceramide 
and a direct precursor of S1P, were markedly higher in Nogo-A/B-
deficient MLECs than in WT MLECs (~50%; Fig. 2b).
Endothelial cells actively produce and secrete S1P12, and intra-
cellular S1P levels are tightly controlled by sphingosine kinases and 
degrading enzymes such as S1P phosphatases and lyase33. In the pres-
ence of phosphatase inhibitors12, S1P levels in the culture medium 
were significantly higher in Nogo-A/B-deficient cells than in WT 
cells (Fig. 2c). Myriocin, a specific inhibitor of SPT, suppressed S1P 
production in both groups (Fig. 2c), suggesting that the de novo 
pathway is responsible for the upregulation of S1P production in 
the absence of Nogo-B. Significantly higher plasma levels of S1P 
in Nogo-A/B-deficient mice than in WT mice corroborated these 
in vitro findings (Fig. 2d).
Next, we studied the interaction between Nogo-B and SPT, 
the rate-limiting enzyme of the de novo sphingolipid biosynthetic 
pathway. First, we expressed HA-tagged Nogo-B and SPTLC1, the 
transmembrane subunit of SPT, in HEK293T cells and found that 
SPTLC1 coimmunoprecipitated with Nogo-B (Fig. 2e). ORMDL20, 
a known SPT-interacting protein, coimmunoprecipitated with 
the Nogo-B–SPT complex, but calnexin did not, indicating that the 
interaction between SPTLC1 and Nogo-B was specific. Nogo-B was 
also immunoprecipitated from mouse lung lysate (Fig. 2f), indicating 
an in vivo interaction between Nogo-B and SPTLC1. Moreover, 
the two proteins colocalized in the tubular ER of COS7 cells trans-
fected with SPTLC1 and HA-tagged Nogo-B (Fig. 2g). To define the 
biological function of the Nogo-B–SPT interaction, we measured 
[3H]serine incorporation into sphinganine (a downstream product 
of the SPT reaction) in endothelial cells and separated the extracted 
sphingolipids by thin layer chromatography (TLC) to assess the enzy-
matic activity of SPT (Supplementary Fig. 2c–e). Genetic deficiency 
of Nogo-B (in MLECs) or small interfering RNA (siRNA)-mediated 
knockdown of Nogo-B (in human umbilical vein endothelial cells 
(HUVECs)) led to an increase in SPT activity (Fig. 2h), which was 
restored to WT levels by lentiviral-mediated expression of Nogo-
B in Nogo-A/B-deficient MLECs (Fig. 2h). To exclude possible 
effects on [3H]serine uptake, we assayed SPT activity in microsomes 
isolated from WT and Nogo-A/B-deficient lungs and confirmed 
that SPT activity was enhanced in the absence of Nogo-A and Nogo-
B (Fig. 2i). Western blot analysis of WT and Nogo-A/B-deficient 
microsomes and soluble fractions showed no difference between the 
two groups in SPTLC1 and calnexin distribution (Supplementary 
Fig. 2f). The Nogo receptor NgBR has been proposed to medi-
ate effects of plasma membrane–localized Nogo-B (<5% of total 
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Figure 4 Lack of Nogo-A/B protects mice from AngII-induced hypertension and  
endothelial dysfunction. (a) Time course of SBP (left) and the increase in SBP over  
the average of basal values (right) measured in conscious WT and Nogo-A/B-deficient  
mice before and after implantation of an osmotic pump delivering AngII. At day 25  
after implantation of osmotic pump, mice were administered myriocin, and their  
blood pressure was measured at days 26, 27 and 28. n = 7 per group.  
(b) Immunofluorescence staining of Nogo-B and isolectin-B4 (IB4) in mesenteric arteries  
from control (top) and hypertensive (bottom) WT mice. Inset, staining of Nogo-B in  
a mesenteric artery from a Nogo-A/B-deficient mouse as a negative control.  
(c,d) Mesenteric arteries from WT and Nogo-A/B-deficient mice treated with AngII  
or vehicle (control) and evaluated for (c) Ach-induced vasodilation (n = 16 WT and  
n = 18 Nogo-A/B-deficient arteries) and (d) effects on Ach-induced vasodilation using l-NAME (left, n = 6 per group), indomethacin (middle, n = 8 per 
group) and l-NAME plus indomethacin (right, n = 8 WT and n = 6 Nogo-A/B-deficient arteries). (e) Plasma levels of nitrites (NOx) in WT and Nogo-A/B-
deficient mice treated with AngII or vehicle (n = 4 per group). (f–h) Mesenteric arteries from WT and Nogo-A/B-deficient mice treated with AngII or vehicle 
and assessed for (f) flow-induced vasodilation (n = 5 per group), (g) vasoconstriction in response to PE (n = 9 WT and n = 6 Nogo-A/B-deficient arteries) 
and (h) myogenic tone (n = 8 per group). (i) WT and Nogo-A/B-deficient mice treated with SEW2871 (3 mg/kg, i.p.) after 4 weeks of chronic infusion of 
AngII. n = 7 per group. Data are expressed as the mean ± s.e.m.; *P < 0.05; **P < 0.01; ***P < 0.001 compared to WT (a,c–i); #P < 0.05 compared to 
WT control (e). Statistical significance was determined by two-way ANOVA followed by Bonferroni’s post hoc test (a,c,d,f–i) or one-way ANOVA (e).
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Nogo-B) on vascular function25. Notably, siRNA-mediated knock-
down of NgBR did not alter the activity of SPT in HUVECs (Fig. 2j), 
suggesting that the intracellular regulation of de novo sphingolipid 
biosynthesis by Nogo-B is not mediated by NgBR.
Nogo-B binds SPT to regulate blood pressure through S1P-S1P1 axis
To confirm the causal role of sphingolipid upregulation in the 
hypotension observed in Nogo-A/B-deficient mice, we inhibited 
SPT activity in vivo with myriocin34 and measured physiological 
outcomes. In Nogo-A/B-deficient mice, a single dose of myriocin 
normalized blood pressure (Fig. 3a), NO plasma levels (Fig. 3b) and 
basal tone in mesenteric arteries ex vivo (Fig. 3c), whereas myriocin 
treatment did not affect the contributions of NO, prostacyclin and 
EDHF to Ach-induced vasodilation (Fig. 3d, Supplementary Fig. 3a 
and Supplementary Data 3). Further, myriocin abolished the differ-
ence in flow-induced dilation between WT and Nogo-A/B-deficient 
mesenteric arteries and increased myogenic tone to the same degree in 
both groups (Fig. 3e). Myriocin did not alter the response of arteries 
to PE, but increased basal tone in both groups, probably owing to 
diminished basal eNOS activation (Fig. 3e). These results indicate 
that upregulation of the de novo sphingolipid biosynthetic pathway 
is the major mechanism responsible for the decrease in vascular 
Figure 5 Lack of endothelial Nogo-B protects mice from AngII-induced hypertension and endothelial dysfunction. (a,b) Nogo-A/Bf/f, EC-Nogo-A/B-deficient  
and SMC-Nogo-A/B-deficient mice analyzed for (a) SBP, diastolic blood pressure (DBP) and mean blood pressure (MBP) (n = 15, n = 13 and  
n = 14 respectively per group) and (b) plasma NO (n = 8 Nogo-A/Bf/f, n = 10 EC-Nogo-A/B-deficient and n = 10 SMC-Nogo-A/B-deficient mice).  
(c–e) Mesenteric arteries from Nogo-A/Bf/f, EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice evaluated for (c) l-NAME–induced decrease in 
luminal diameter versus baseline (n = 9 Nogo-A/Bf/f, n = 14 EC-Nogo-A/B-deficient and n = 7 SMC-Nogo-A/B-deficient mice), (d) vasodilation to Ach 
without or with l-NAME (n = 7 Nogo-A/Bf/f, n = 5 EC-Nogo-A/B-deficient and n = 6 SMC-Nogo-A/B-deficient mice) and (e) flow-induced vasodilation 
(left; n = 7 Nogo-A/Bf/f, n = 8 EC-Nogo-A/B-deficient and n = 5 SMC-Nogo-A/B-deficient mice) and myogenic tone (right; n = 6 Nogo-A/Bf/f, n = 11  
EC-Nogo-A/B-deficient and n = 6 SMC-Nogo-A/B-deficient mice). (f) Nogo-A/Bf/f, EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice, before  
and after implantation with osmotic pumps delivering AngII, analyzed for SBP (left) and the increase in SBP over the average of basal values (right;  
n = 8 Nogo-A/Bf/f, n = 7 EC-Nogo-A/B-deficient and n = 9 SMC-Nogo-A/B-deficient mice). (g) Dose-response curves to Ach of mesenteric arteries from 
AngII-treated Nogo-A/Bf/f, EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice (n = 8 Nogo-A/Bf/f mice treated with vehicle (control), n = 10  
Nogo-A/Bf/f, n = 9 EC-Nogo-A/B-deficient and n = 11 SMC-Nogo-A/B-deficient mice treated with AngII). (h) Plasma levels of nitrites in Nogo-A/Bf/f,  
EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice treated with AngII or vehicle (control) (n = 8 Nogo-A/Bf/f, n = 7 EC-Nogo-A/B-deficient and 
n = 7 SMC-Nogo-A/B-deficient mice per condition). (i) Mesenteric arteries from Nogo-A/Bf/f, EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice 
treated with AngII or vehicle (control) were assessed for flow-induced vasodilation (left; n = 7 Nogo-A/Bf/f, n = 8 EC-Nogo-A/B-deficient and n = 5  
SMC-Nogo-A/B-deficient mice per control group and n = 9 Nogo-A/Bf/f, n = 8 EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice per AngII group) 
and myogenic tone (right; n = 6 Nogo-A/Bf/f, n = 11 EC-Nogo-A/B-deficient and n = 6 SMC-Nogo-A/B-deficient mice per control group, and n = 6  
Nogo-A/Bf/f, n = 11 EC-Nogo-A/B-deficient and n = 9 SMC-Nogo-A/B-deficient mice per AngII group). Data are expressed as mean ± s.e.m.; **P < 0.01; 
***P < 0.001 compared to WT (a–i); ##P < 0.01, AngII vs. control; †P < 0.05, AngII vs. control (h); ###P < 0.001, EC-Nogo-A/B-deficient vs.  
Nogo-A/Bf/f (i). Statistical significance was determined by one-way ANOVA (a–c,h) or two-way ANOVA followed by Bonferroni’s post hoc test (d–g,i).
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resistance and hypotension in Nogo-A/B-deficient mice, through 
regulation of flow-mediated vasodilation and myogenic tone.
S1P produced in the endothelium is transported out of the cell to 
activate the S1P1-eNOS pathway12,30. eNOS-derived NO is a major 
effector of S1P-mediated S1P1 activation (Supplementary Fig. 3b). 
To investigate more directly the role of autocrine S1P-S1P1-eNOS 
signaling in endothelial cells in the regulation of vascular tone, we 
used W146, a known antagonist of S1P1 (half-maximal inhibitory 
concentration (IC50) of 70 nM) (Fig. 3f). In WT mesenteric arteries, 
W146 treatment reduced basal eNOS activation and increased basal 
tone and vasoconstriction in response to PE (Supplementary Fig. 3c–e), 
whereas it did not affect the contributions of prostacyclin, NO 
and EDHF to Ach-induced vasodilation (Supplementary Fig. 3f,g). 
Notably, at a concentration of 1 µM, W146 blunted flow-mediated 
vasodilation and significantly increased myogenic tone in WT 
mesenteric arteries (Fig. 3f). The importance of S1P1 to the flow-
mediated response has previously been reported for endothelial 
cells in culture12. Our results with W146 demonstrate the direct role of 
S1P1 receptors in the response to blood flow in resistance vessels and 
implicate an augmented myogenic tone as a counteracting response 
to the loss of flow-induced vasodilation.
On the basis of these findings, we hypothesized that an endothelial 
S1P-S1P1-eNOS autocrine loop is upregulated in Nogo-A/B-deficient 
mesenteric arteries and that this upregulation accounts for the 
increase in flow-induced dilation and NO release. In this scenario, we 
would expect high activation of S1P1 receptors in Nogo-A/B-deficient 
mesenteric arteries under baseline conditions. Indeed, the increase 
of vascular tone was greater in Nogo-A/B-deficient than in WT 
mesenteric arteries after W146 treatment (Fig. 3g), indicating a gain 
of S1P1 signaling in the absence of Nogo-B. Notably, partial inhibition 
of S1P1 by W146 normalized the flow response and myogenic tone 
of Nogo-A/B-deficient mesenteric arteries (Fig. 3h). Upregulation of 
an S1P-S1P1-eNOS autocrine loop in absence of Nogo-A and Nogo-
B was further corroborated by the observation that S1P-induced 
vasodilation was markedly reduced in Nogo-A/B-deficient mesenteric 
arteries as compared to WT (Fig. 3i). Moreover, myriocin treatment 
increased the sensitivity of WT and Nogo-A/B-deficient mesenteric arter-
ies to S1P to the same degree (Fig. 3i), and S1P1 expression was similar 
between the two groups (Fig. 3j). Taken together, these findings sug-
gest a protective role of S1P signaling and indicate that hyperactiva-
tion of endothelial S1P-S1P1-eNOS autocrine signaling accounts for 
the reduced vascular tone observed in the absence of Nogo-B.
Nogo-B mediates vascular dysfunction in hypertension
To assess the importance of Nogo-B in pathological conditions, we 
employed the angiotensin II (AngII)-induced model of hyperten-
sion, which recapitulates features of human hypertension, including 
vascular dysfunction35–37. Chronic infusion of AngII produced 
robust and sustained hypertension in WT mice, whereas it induced 
only a mild increase in blood pressure in Nogo-A/B-deficient mice 
(Fig. 4a). Notably, myriocin administration raised the blood pressure 
of AngII-treated Nogo-A/B-deficient mice to that of AngII-treated 
WT mice (Fig. 4a).
Immunofluorescence staining of mesenteric arteries revealed 
that Nogo-B was expressed in both endothelial cells and VSMCs in 
vehicle-treated WT mice and that Nogo-B levels were much lower in 
VSMCs but unchanged in endothelial cells in the mesenteric arteries 
of hypertensive (AngII-treated WT) mice (Fig. 4b). These findings 
suggest that Nogo-B exerts pro-hypertensive effects in endothelial 
cells rather than in VSMCs.
Consistent with these in vivo findings, mesenteric arteries 
from AngII-treated Nogo-A/B-deficient mice were protected from 
endothelial dysfunction, showing preserved vasorelaxation in 
response to Ach and preserved NO production, with no difference in 
the contribution of prostacyclin and EDHF to Ach-induced vasodila-
tion (Fig. 4c–e), and a sustained vasodilatory response to blood flow 
(Fig. 4f). Mesenteric arteries from WT mice showed greater myogenic 
tone and increased vasoconstriction in response to PE than did those 
from Nogo-A/B-deficient mice (Fig. 4g,h).
Finally, to directly assess the protective role of S1P1 signaling in 
hypertension, we injected AngII-treated WT and Nogo-A/B-deficient 
mice with SEW2871, a selective agonist of S1P1. SEW2871 administration 
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Figure 6 Endothelial Nogo-B is a critical  
mediator of hypertension and vascular  
dysfunction through negative regulation  
of sphingolipid de novo biosynthesis. 
Endothelial-derived S1P has a crucial  
function in flow-mediated vasodilation  
through an autocrine S1P1-eNOS signaling 
axis. S1P is transported out of endothelial  
cells, where it activates S1P1-eNOS pathway  
in an autocrine fashion, leading to NO 
production and blood pressure regulation. 
Left, in the absence of Nogo-B, SPT activity 
is enhanced and endothelial cells produce 
increased amounts of S1P, resulting in  
increased flow-mediated vasodilation and 
decreased basal tone. Myriocin, a specific 
inhibitor of SPT, and W146, an S1P1  
antagonist, reinstate the normal response to 
blood flow and pressure in Nogo-A/B-deficient  
resistance arteries. SEW2871, an agonist  
of S1P1, lowers blood pressure in hypertensive 
mice. Right, the lack of Nogo-B in smooth 
muscle cells leads to an increase in 
sphingolipid biosynthesis and ceramide  
levels, resulting in decreased myogenic  
tone. EC, endothelial cell.
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led to a marked hypotensive response in WT but not Nogo-A/B- 
deficient mice; the blood pressure of AngII-treated Nogo-A/B- 
deficient mice was close to normal values (Fig. 4i). These data dem-
onstrate that in a hypertensive model, Nogo-B negatively regulates 
the de novo pathway of sphingolipid biosynthesis in the vasculature, 
leading to endothelial dysfunction and higher blood pressure.
Endothelial Nogo-B promotes vascular dysfunction and hypertension
To dissect the roles of Nogo-B in endothelial and smooth muscle cells, 
we generated mice lacking Nogo-A and Nogo-B specifically in endothe-
lial cells or in smooth muscle cells. We first generated mice with a loxP-
flanked allele of the gene encoding Nogo-A and Nogo-B (Nogo-A/Bf/f). 
We then bred these mice to mice expressing Cre recombinase specifi-
cally in endothelial or smooth muscle cells to generate endothelial cell 
(EC)- or smooth muscle cell (SMC)-Nogo-A/B-deficient mice (Online 
Methods). We documented a near-complete loss of Nogo-B mRNA 
expression and protein expression in endothelial cells and smooth mus-
cle cells in EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice, 
respectively (Supplementary Fig. 4a–g and Supplementary Data 4). 
As reported by other groups25,38, Nogo-A is not detectable in endothe-
lial cells; thus, the phenotype observed in EC-Nogo-A/B-deficient mice 
can be ascribed to the specific loss of Nogo-B.
The lack of Nogo-B in endothelial cells and, to a lesser extent, in 
smooth muscle cells, led to a marked reduction in baseline blood 
pressure (Fig. 5a), recapitulating the effects observed in systemic 
Nogo-A/B-deficient mice and suggesting that Nogo-B acts predomi-
nantly in endothelial cells to regulate systemic blood pressure. We 
observed increased plasma levels of NO and increased basal and Ach-
stimulated production of NO in mesenteric arteries specifically in 
EC-Nogo-A/B-deficient mice, whereas myogenic tone (but not PE-
induced vasoconstriction) (Supplementary Fig. 4h) was significantly 
reduced in mesenteric arteries from SMC-Nogo-A/B-deficient mice 
(Fig. 5b–e). These results indicate that endothelial Nogo-B affects 
flow-induced vasodilation through the S1P-S1P1-eNOS axis, whereas 
smooth muscle Nogo-B regulates myogenic tone. EC-Nogo-A/B-
deficient mice were protected from AngII-induced hypertension 
and endothelial dysfunction, with preserved production of NO under 
baseline and Ach-stimulated conditions, and had a preserved vasodila-
tory response to flow (Fig. 5f–i). AngII-treated SMC-Nogo-A/B- 
deficient mice developed a milder hypertension than did Nogo-A/Bf/f 
control mice, probably because of a reduced myogenic tone; however, 
SMC-Nogo-A/B-deficient mice showed endothelial dysfunction and 
impaired flow-mediated vasodilation, similarly to control Nogo-A/Bf/f 
mice (Fig. 5f–i). Ceramide-activated serine-threonine phosphatases 
(CAPPs) such as phosphatase 1 (PP1) and phosphatase 2A (PP2A), 
which have a defined role in smooth muscle cell contractility39, have 
been found to interact with ceramide40. Increased levels of cer-C18, 
cer-C20 and cer-C22 in smooth muscle cells of SMC-Nogo-A/B- 
deficient mice may therefore be responsible for the reduced 
myogenic tone observed in these mice. Together, these findings 
suggest that Nogo-B, acting predominantly in endothelial cells, 
contributes to vascular dysfunction and hypertension (Fig. 6).
DISCUSSION
Dysfunction of the endothelium is associated with hypertensive cardio-
vascular disease and probably precedes its development3,41. Recently, 
bioactive sphingolipids, and S1P in particular, have been shown to 
regulate important aspects of cardiovascular pathophysiology, includ-
ing angiogenesis, vascular tone and endothelial barrier integrity42–44. 
Although altered sphingolipid signaling has been implicated in 
endothelial dysfunction and cardiovascular disease42,45, the specific 
molecular mechanisms involved are still poorly understood.
Our study identifies Nogo-B as a negative regulator of the de novo 
pathway of sphingolipid biosynthesis, independently of NgBR46. We 
found that Nogo-B binds to and inhibits the activity of SPT, the rate-
limiting enzyme of the pathway. Thus, loss of a Nogo-B–mediated 
brake on SPT leads to an increase in locally produced sphingolipids 
and S1P in the endothelium, exerting vasculoprotective effects.
Indeed, S1P is a potent activator of eNOS through S1P1 and S1P3, 
and many of the beneficial effects of S1P on the vasculature are medi-
ated by NO, including cell survival, proliferation and migration47,48. 
Our data on the S1P1 antagonist W146 corroborate the role of S1P1 in 
blood flow–induced dilation in resistance vessels and provide direct 
evidence of the importance of endothelial-derived S1P in control-
ling vascular response to flow through an autocrine-paracrine loop 
involving S1P1-eNOS signaling.
To date, the impact of S1P receptor modulators on cardiovascular 
pathophysiology remains largely unexplored. Here, we reveal anti-
hypertensive effects of S1P1 signaling, identifying a potential thera-
peutic target for the treatment of this pathological condition. Recently 
S1P receptor modulation has become an attractive pharmacological 
target49–51. Our findings suggest that potential cardiovascular effects 
should be a consideration in the development of such agents.
Although much attention has been devoted to the sphingolipid 
recycling pathway and the role of sphingomyelinase in cardiovascu-
lar disease52, relatively little attention has been paid to the function 
of the de novo pathway in this context. Our studies reveal a protec-
tive function of the de novo pathway within the vasculature in the 
pathogenesis of hypertension. The production of endothelial S1P is 
strongly sustained by the de novo pathway; indeed, we found that the 
SPT inhibitor myriocin reduced S1P levels in the culture medium of 
endothelial cells by ~50% after only 4 h of incubation, and a single dose 
of myriocin normalized the blood pressure of Nogo-A/B-deficient 
mice and restored blood flow–induced vasodilation, myogenic tone 
and NO production of mesenteric arteries. Our pharmacological data 
using the S1P1 antagonist W146 and an SPT inhibitor myriocin indicate 
the importance of local S1P-S1P1-eNOS signaling in the regulation 
of vascular tone in both normal physiology and hypertension. 
Moreover, the ability of the selective S1P1 antagonist SEW2871 to nor-
malize blood pressure in hypertensive mice reveals the critical role of 
S1P1-mediated signaling in hypertension.
Genome-wide association studies have identified a strong association 
between the ORMDL locus and the incidence of childhood asthma22, 
and Orm proteins in yeast (ORMDL proteins in human) have recently 
been identified as negative regulators of SPT20. We found that ORMDL 
coimmunoprecipitated with Nogo-B and SPTLC1, suggesting that these 
proteins are part of the same complex. Moreover, Nogo-A and Nogo-B 
deficiency led to an increase in microsomal SPT activity in the lung, 
suggesting that Nogo-B is a regulatory factor of SPT.
Despite expression of Nogo-B in both endothelial and smooth 
muscle cells, Nogo-B has a selective impact on sphingolipid synthesis 
in endothelial cells, particularly with respect to the steady-state levels 
of cer-C18, cer-C20 and cer-C22. This selective effect may be due 
to differential contributions of the de novo pathway of sphingolipid 
biosynthesis in endothelial cells and VSMCs, differential regulation 
of sphingolipid biosynthesis depending on cell type and pathological 
conditions, or cell type–specific functioning of Nogo-B.
Our findings in resistance arteries from systemic and EC-Nogo-A/B-
deficient mice indicate the important role of Nogo-B in vascular tone 
regulation by control of local sphingolipid production. In a recent study, 
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a specific extracellular domain of Nogo-A was proposed to activate S1P2 
in the brain53. The S1P2 receptor is also expressed in VSMCs11; however, 
Nogo-A is undetectable in the mouse aorta and femoral artery25, excluding 
the possibility that the vascular phenotype of Nogo-A/B-deficient 
mesenteric and carotid arteries is due to lack of Nogo-A–mediated sig-
naling in the vasculature. Although our data in Nogo-A/B-deficient mice 
do not rule out a possible contribution of Nogo-A, which is enriched in 
the brain, in the control of blood pressure, the hypotension of EC-Nogo-
A/B-deficient mice and their resistance to hypertension and vascular 
dysfunction can be attributed to endothelial-expressed Nogo-B.
The finding that Nogo-B regulates sphingolipid signaling provides a 
framework for investigating whether alterations of Nogo activity and 
sphingolipid metabolism contribute to other pathological conditions 
that have been reported in mice lacking Nogo-B, including vascu-
lar injury25, asthma54 and liver fibrosis55 and inflammation56. The 
observation that Nogo-B controls sphingolipid metabolism strongly 
suggests that dysregulation of this signaling pathway may have a 
causative role in the pathogenesis of hypertension and endothelial 
dysfunction leading to cardiovascular disease. Most notably, the iden-
tification of regulatory mechanisms for endothelial sphingolipid pro-
duction may allow for targeted pharmacological intervention of these 
pathways in cardiovascular disease.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Animals. Nogo-A/B-deficient mice were generated as previously described24. 
To generate Nogo-A/Bf/f mice, we inserted loxP sites into the Rtn4 gene to flank 
exons 2 and 3; the targeted region was about 3.29 kb in length. The proximal 
loxP cassette was placed 186 bp upstream of exon 2, in intron 1–2, and the 
distal loxP cassette was placed 237 bp downstream of exon 3, in intron 3–4.
Mice lacking Nogo-A/B specifically in endothelial cells (EC-Nogo-A/B-
deficient) were obtained by crossing Nogo-A/Bf/f mice with transgenic mice 
in which the VE-cadherin promoter drives expression of tamoxifen-responsive 
Cre (VE-Cad-CreERT2)57 such that tamoxifen treatment selectively deletes the 
loxP-flanked (‘floxed’) region of Rtn4 in endothelial cells. Mice lacking Nogo-A/B 
specifically in smooth muscle cells (SMC-NogoA/B-deficient) were obtained by 
crossing Nogo-A/Bf/f mice with transgenic mice in which the α-smooth muscle 
actin promoter drives expression of Cre (SM22α-Cre) (Tagln-Cre 1Her/J, The 
Jackson Laboratory, Bar Harbor, Maine; cat. 004746). Mice from both strains 
were born with Mendelian frequencies. To induce Nogo-A/B deficiency in 
endothelial cells, male and female NogoA/Bf/f-VE-Cad-CreERT2-positive and 
NogoA/Bf/f-VE-Cad-CreERT2-negative littermates were injected intraperito-
neally (i.p.) with 6 mg/kg of tamoxifen daily for 5 d at the age of 6–8 weeks. 
The extent of Cre-mediated excision of exon 2 and 3 of Rtn4 in endothelial cells 
and VSMCs was confirmed by real-time PCR on endothelial cells isolated from 
mouse lungs and on endothelial cell and VSMC mRNA isolated from the tho-
racic aorta of NogoA/Bf/f, EC-NogoA/B-deficient and SMC-NogoA/B-deficient 
mice. All animal experiments were approved by the Weill Cornell Institutional 
Animal Care and Use Committee. The experiments were not randomized; inves-
tigators were blinded for blood pressure measurements by tail-cuff system but 
not for allocation during experiments and outcome assessment.
Blood pressure measurements in conscious mice. Systolic, diastolic and mean 
blood pressure was measured in conscious 12-week-old male mice using the 
pneumatic tail-cuff method (MRBP System, Life Science, Woodland Hills, 
California). Briefly, animals were placed in a plastic chamber maintained at 
34 °C and a cuff with a pneumatic pulse sensor was attached to the tail. After 
1 week of training, three consecutive measurements were performed per mouse, 
and the values were averaged. In another set of experiments, mice were injected 
with myriocin (0.3 mg/kg i.p., Sigma) or vehicle (0.4% fatty acid–free BSA) and 
blood pressure was measured 1 d later.
Evaluation of vascular reactivity in pressure myograph. Carotid and 
second-order mesenteric arteries isolated from male mice at 10–12 weeks of age 
were carefully cleaned from adhering tissue and mounted on glass micropipettes 
in a pressure myograph chamber (Danish MyoTechnology, Aarhus, Denmark); 
the orientation of the vessel in relation to the flow in vivo was maintained. 
Viability of the vessels was maintained using Krebs solution (in mM: NaCl 118, 
KCl 4.7, MgCl2 1.2, KH2PO4 1.2, CaCl2 2.5, NaHCO3 25 and glucose 10.1), 
at 37 °C and oxygenated (95% O2 and 5% CO2).
The micropipette was connected to a pressure interface, which regulated 
intraluminal pressure and flow. The vessel diameter was monitored in real 
time using a microscope connected to a digital video camera (IC Capture) and 
computer software with edge detection capability. Mesenteric arteries were equil-
ibrated for 30 min at 80 mm Hg, preconstricted with PE (1 µM) and a cumulative 
concentration-response curve of Ach (1 × 10−9–3 × 10−5 M) was performed to 
evaluate the integrity and the function of the endothelium. Normotensive vessels 
with less than 80% vasodilatory response to Ach were discarded.
To evaluate the vasoconstriction of mesenteric arteries, cumulative 
concentration-response curves were performed with PE (1 × 10−9–3 × 10−5 M, 
Sigma), U-46619 (1 × 10−12–10−6 M, Sigma) and S1P (1 × 10−9–10−6 M, Avanti 
Polar Lipids); to assess the vasodilation of mesenteric arteries, cumulative con-
centration curves were performed with Ach (1 × 10−9–3 × 10−5 M) and S1P 
(1 × 10−12–3 × 10−9 M). The cumulative concentration-response curve for Ach 
was performed in the presence of l-NAME (NOS inhibitor; 100 µM, Sigma), 
indomethacin (COX inhibitor; 10 µM, Sigma) and a combination of both, added 
in Krebs buffer (mM: NaCl 118, KCl 4.7, MgCl2 1.2, KH2PO4 1.2, CaCl2 2.5, 
NaHCO3 25 and glucose 10.1).
The myogenic response was measured using a stepwise increase of intralu-
minal pressure (20, 45, 70, 95, 120 mm Hg); each pressure level was maintained 
for 5 min. At the end of the experiment, a myogenic curve was performed in 
Ca2+-free Krebs buffer supplemented with 1 mM EGTA. Myogenic tone (%) was 
expressed as [(D1 − D2)/D1] × 100, where D1 is the passive diameter in Ca2+-free 
Krebs buffer and D2 is the active diameter in complete Krebs buffer, at the same 
intraluminal pressure.
Flow-mediated vasodilation was measured using preconstriction of mesenteric 
arteries with PE (3 × 10−7 M) at 95 mm Hg of mean pressure. Intraluminal flow 
was increased in steps of 25 µl/min from 0 to 125 µl/min. Flow was maintained 
for 5 min at each step. Measurements of myogenic tone and flow-mediated 
vasodilation were repeated after 45 min of incubation of mesenteric arteries with 
1 µM or 100 nM W146 (Sigma), a selective and reversible S1P1 inhibitor. Carotid 
arteries were assessed for vasoconstriction induced by increasing concentra-
tion of PE (1 × 10−9–3 × 10−5 M). To evaluate the vasodilation induced by flow, 
carotid arteries were preconstricted with a concentration of PE inducing 60% of 
the maximum vasoconstriction achieved in the concentration-response curve 
to PE, followed by a stepwise increase of flow (0 to 800 µl/min).
Vessel morphometry and immunostaining. Following full relaxation with 
Ach (1 × 10−6 M), mesenteric arteries were fixed with 4% PFA and left 
overnight at 4 °C. The elastic lamina of paraffin-embedded mesenteric arter-
ies was visualized with Verhoeff ’s Van Gieson (VVG) staining. Wall thickness, 
area and radius were determined by using a computerized image-analysis 
system (Image-Pro).
PFA-fixed mesenteric arteries were paraffin-embedded or OCT-embedded. 
For immunohistochemistry, following deparaffinization and antigen retrieval, 
mesenteric artery sections were incubated overnight with antibody against 
Nogo-B (#AF6034, R&D, 1:100) followed by anti-sheep antibody (#713-065-
003, Jackson ImmunoResearch, 1:200). Staining was developed with diami-
nobenzidene (DAB). Finally, the sections were counterstained with Mayer’s 
hematoxylin solution.
For immunofluorescence, frozen mesenteric artery sections were stained 
for Nogo-B (1:100, R&D) and biotinylated IB4 (1:100, BD Biosciences) over-
night at 4 °C, and were then stained with Cy3-labeled anti-sheep antibody 
(#A21436, Invitrogen, 1:200) and streptavidin–Alexa 488 (#016-540-084, 
Jackson ImmunoResearch, 1:200) in PBS for 1 h. Nuclei were stained with 
DAPI. Confocal immunofluorescence images of the tissues were captured on 
an Olympus Fluoview confocal microscope.
NOx assay. Male mice of 10–14 weeks of age were anesthetized with ketamine 
(150 mg/kg) and xylazine (15 mg/kg). Whole blood was collected in EDTA 
via cardiac puncture. Plasma was obtained by centrifugation at 1,000 × g for 
15 min at 4 °C and was immediately collected and snap frozen in liquid 
nitrogen to preserve NO content.
NO levels were measured as nitrite in plasma from WT, Nogo-A/B-deficient, 
NogoA/Bf/f, EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice, with 
or without AngII infusion, using a modified Griess reaction58. Briefly, after 
precipitation of plasma proteins with ZnSO4 (30% w/v), supernatants were 
chemically reduced with acid-washed (0.24 M HCl) cadmium powder (Sigma- 
Aldrich). After centrifugation, samples were measured for nitrite content with 
Griess reagent (0.1% naphtylethylendiamine dihydrochloride in H2O and 1% 
sulfaniamide in 5% concentrated H3PO4) and read at a wavelength of 550 nm. 
All samples were assayed in duplicate and the NO concentration was calculated 
against an NaNO2 calibration curve (0.31, 0.62, 1.25, 2.5, 5, 10, 20, 40, 80 µM).
cGMP measurements. cGMP levels were measured in WT and Nogo-A/B- 
deficient aortas isolated from male mice at 10–14 weeks of age. Briefly, the aorta 
was dissected and cleaned from surrounding fat tissue, cut into rings 2 mm 
in length, and incubated in Krebs at 37 °C for 30 min. After that, rings were stim-
ulated with the Ca2+ ionophore A23187 (10 µM, Sigma) for 3 min and were then 
rapidly weighed and snap frozen in liquid nitrogen. Tissues were homogenized 
with 20 volumes of 5% trichloroacetic acid (TCA) per gram of tissue and cen-
trifuged at 1,500 × g for 10 min. The supernatant was collected and treated with 
5 volumes of water-saturated diethylic ether (repeated twice) to extract residual 
TCA. The samples were warmed for 5 min at 70 °C to remove any residual ether. 
The cGMP content of the samples was measured by enzyme immunoassay, using 
a kit according to the manufacturer’s instructions (Cayman, CA).
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En face aorta immunostaining. Aortas were isolated from male mice at 10–14 
weeks of age and immunostaining for eNOS, phosphorylated eNOS and S1P1 
receptor was performed as previously described17.
SMC isolation from mouse aorta. Aortic SMCs were isolated from aortas of 
5 WT and 5 Nogo-A/B-deficient male mice at 6–8 weeks of age. Briefly, aortas 
were cleaned of connective tissue and the adventitia was digested with type II 
collagenase (Worthington 1 mg/ml) dissolved in DMEM (20 min, 37 °C), fol-
lowed by its manual removal. Aortas were minced and digested in 0.1 mg/ml 
elastases (Sigma) and 1 mg/ml collagenase II in DMEM (2 h, 37 °C). VSMCs 
were cultured in DMEM containing 10% FBS. When cells reached confluence, 
the medium was replaced with 10% charcoal-stripped DMEM for 24 h. Cell 
lysates were collected in lysis buffer as previously described56 and were analyzed 
for sphingolipid content by the Lipidomic Core Facility of the Medical University 
of South Carolina.
Endothelial cell isolation from mouse lung tissue. Primary endothelial cells 
from the lungs (MLECs) of female and male WT, Nogo-A/B-deficient, Nogo-
A/Bf/f and EC-Nogo-A/B-deficient mice at 6–10 weeks of age were isolated as 
previously described56. The culture medium was replaced with EBM-2 medium 
supplemented with growth factors (#J64516) and 10% charcoal-stripped FBS for 
24 h and cell lysates were collected in lysis buffer as previously described56. Cell 
lysates were analyzed for sphingolipid content by the Lipidomic Core Facility of 
the Medical University of South Carolina. MLECs isolated from Nogo-A/Bf/f and 
EC-Nogo-A/B-deficient mice were collected, cell lysate was collected in RIPA 
buffer, and western blotting was performed for Nogo-B protein.
Lentivirus construction. Murine HA-tagged Nogo-B (NCBI AAM77069) 
was synthesized by Genewiz and inserted in the lentiviral vector pCDH-CMV-
MCS-EF1-Puro (Addgene). Lentiviral particles containing the construct 
encoding HA-tagged Nogo-B were produced in HEK293T cells transfected 
with Oligofectamine 2000 (Invitrogen). Viral particles were harvested from 
the culture supernatant 72h after transfection, passed through a 0.45-µm filter 
and concentrated by adding PEG-it virus precipitation solution (#LV810A-1, 
System Biosciences) overnight at 4 °C followed by centrifugation at 1,500 × g for 
30 min. Viral pellets were resuspended in DMEM (#D6429, Sigma) and stored 
at −80 °C until use.
Cell culture and transfection. HEK293T cells were cultured in DMEM (#D6429, 
Sigma) with high glucose (4,500 mg/L) supplemented with 10% FBS, penicillin 
and streptomycin (pen/strep, Sigma). Cells were maintained at 37 °C and 5% 
CO2 in a humidified incubator. Transfections were as follows: 0.4 × 106 cells 
were transfected with 2 µg HA-tagged Nogo-B plasmid and 2 µg of SPTLC1 
plasmid (#MMM1013-202805259, MGC Mouse Sptlc1 cDNA, GE Healthcare-
Dharmacon) using Lipofectamine 2000 (#11668-019, Invitrogen) following 
the manufacturer’s protocols. Cells were harvested 48 h after transfection and 
coimmunoprecipitation of Nogo-B and SPTLC1 was assessed.
Monkey kidney COS7 cells were cultured in DMEM (Sigma) with high glu-
cose (4,500 mg/L) supplemented with 10% FBS and penicillin and streptomycin 
(pen/strep, Sigma). Cells were maintained at 37 °C and 5% CO2 in a humidi-
fied incubator. Transfections were as follows: 0.4 × 106 cells were transfected 
with 2 µg HA-tagged Nogo-B plasmid and 2 µg of SPTLC1 plasmid using 
Lipofectamine 2000 following the manufacturer’s protocols. 48 h after transfec-
tion, cells were fixed with 4% PFA and stained for anti-HA (1:100, #11815016001, 
Roche) and SPTLC1 (1:100, #611304; BD Biosciences) antibodies overnight at 
4 °C, and were then stained with Alexa Fluor 594–labeled anti-rat antibody 
(#A21209, Invitrogen) and streptavidin–Alexa 488 (#016-540-084, Jackson 
ImmunoResearch, 1:200) in PBS for 1 h. Nuclei were stained with DAPI.
NgBR knockdown in HUVECs by siRNA transfection. siRNA targeting the 
Nogo-B receptor (NgBR; forward: GGAAAUACAUAGACCUACA, reverse: 
UGUAGGUCUAUGUAUUUCC) and control (forward: UUCUCCGAACG 
UGUCACG, reverse: ACGUGACACGUUCGGAGAA) were synthesized by 
Qiagen. HUVECs were transfected with siRNA using Oligofectamine trans-
fection reagent (Invitrogen). Expression of NgBR (analyzed by western blotting) 
and the enzymatic activity of SPT were assessed 72 h after transfection.
Measurement of S1P in medium. Confluent WT and Nogo-A/B-deficient 
MLECs were incubated with DMEM containing 10% charcoal-stripped FBS, 
10 mmol/L sodium glycerophosphate, 5 mmol/L sodium fluoride and 1 mmol/L 
semicarbazide12 for 4 h. In another set of experiments, MLECs were treated with 
myriocin (100 nM) dissolved in 0.1% fatty acid–free BSA or vehicle. After 20 h, 
10 mmol/L sodium glycerophosphate, 5 mmol/L sodium fluoride and 1 mmol/L 
semicarbazide5 were added to the MLECs, and 4 h later the culture medium was 
collected and analyzed for S1P content by the Lipidomic Core Facility of the 
Medical University of South Carolina.
Sphingolipid analysis by LC-MS/MS. Plasma, medium, endothelial cell and 
VSMC lysates were used for quantification of sphingolipids by LC-MS/MS. The 
levels of ceramide (Cer) species, sphingosine (Sph) and S1P were analyzed by 
the Lipidomics Analytical Core at the Medical University of South Carolina as 
previously described59.
Western blot and immunoprecipitation. Western blot and immunoprecipi-
tation analyses were performed as previously described56. For western blot 
analysis, the following primary antibodies were used: Nogo-B (#AF-6034; R&D, 
Minneapolis, MN, dilution 1:1,000); eNOS, SPTLC1 and Hsp90 (#610297, 
#611304 and #610419; BD, Biosciences, San Jose, CA; dilution 1:1,000); nNOS 
and phospho-S1176-eNOS (#C12H1 and #9571s respectively; Cell Signaling 
Technology, Danvers, MA; dilution 1:1,000); anti-HA (#11867423001; Roche, 
Nutley, NJ; dilution 1;1,000); S1P1, c-Myc, ORMDL1/2/3, VE-cadherin and 
NgBR (#sc-25489, 1:2,000; #sc-40, 1:1,000; #sc-161143, #sc-6458, 1:1,000; 
and #sc138044 1:1,000, respectively; Santa Cruz Biotechnology, Santa Cruz, 
CA); Calnexin (#ADI-SPA-860-D; ENZO, Farmingdale, NY; dilution 1:1,000); 
α-SMA and β-actin (#5228 and #A2228; Sigma Aldrich, St. Louis, MO; 
dilution 1:2,000); anti-GFP (#ab6556; abcam, Cambridge, MA; dilution 
1:1,000). For immunoprecipitation analysis, the following antibodies were 
used: Nogo-B (#AB-163; Kinasource, Scotland, UK; dilution 1:100) and 
anti-HA (#11815016001; Roche; dilution 1:100).
Microsomal isolation from mouse lung. Microsomal fractions were obtained 
from WT and Nogo-A/B-deficient lungs as previously described60. Briefly, a 
volume of 50 mM HEPES buffer (pH 7.4 at 4 °C), 0.25 M sucrose, and 5 mM 
EDTA (pH adjusted to 7.4 with NaOH) was added to the lung (equal to the lung 
weight, 1 g/ml). Additional buffer was added to yield a 20% (w/v) suspension 
and the lung was homogenized with three 15-s treatments with a Brinkman 
Polytron PT20. The homogenates were centrifuged for 15 min at 18,000 × g at 
4 °C, and the resulting supernatants were centrifuged for 1 h at 100,000 × g. The 
microsomal pellets were then resuspended by adding 1 ml of buffer (50 mM 
HEPES (pH 7.4 at 25 °C), 5 mM EDTA (pH 7.4), 5 mM DTT and 20% (w/v) 
glycerol) per gram of lung tissue used for the microsome preparation.
Serine palmitoyltransferase (SPT) activity. SPT activity in lung tissue was 
measured as previously described60. Briefly, the assay was conducted in a volume 
of 0.1 ml that contained: 0.1 M HEPES (pH 8.3 at 25 °C), 5 mM DTT, 2.5 mM 
EDTA (pH 7.4), 50 µM pyridoxal 5′-phosphate (PLP; Sigma), 0.45 µM [3H]serine 
(PerkinElmer), 0.2 mM palmitoyl-CoA (Sigma) and 50 µg microsomes. The 
control reaction contained all of the above components except palmitoyl-CoA. 
The samples were incubated for 10 min at 37 °C and the reaction was stopped 
with 0.2 ml of 0.5 N NH4OH, followed by 50 µl of NaBH4 (5 mg/ml) to convert 
the reaction product 3-ketosphinganine into sphinganine. Radiolabeled lipid 
products were extracted by using a modification of Bligh and Dyer’s method61. 
Briefly, 0.7 ml CHCl3 and methanol (1:2) was added, followed by CHCI3 and 
0.5 N NH4OH (1:1). After centrifugation, the lower layer containing lipids 
was collected and the organic solvent was removed under a gentle stream of 
nitrogen gas. The samples were dissolved in CHCl3 and analyzed by thin-layer 
chromatography.
For measurement of SPT activity in HUVECs and MLECs isolated from WT 
and Nogo-A/B-deficient mice, the cells were grown to confluence in 60-mm 
dishes and starved in endothelial growth basal medium (EBM2) medium for 3 h. 
After washing twice with PBS, the cells were suspended in SPT reaction buffer 
(1 M HEPES (pH 8.3 at 25 °C), 5 mM DTT, 2.5 mM EDTA (pH 7.4) and 50 µM 
pyridoxal 5′-phosphate) and sonicated for 15 s. Cell lysates (200 µg) were mixed 
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with 0.45 µM [3H]serine and 0.2 mM palmitoyl-CoA. As a negative control, 
an aliquot of cell lysate was treated with myriocin (100 nM) for 6 h. The reac-
tion was carried out for 10 min at 37 °C and stopped by the addition of NaBH 
(5 mg/ml) for 5 min at room temperature. The radiolabeled lipid products were 
extracted using the modified Bligh and Dyer’s method, as described above.
Thin-layer chromatography analysis. Separation and quantification of lip-
ids was performed by thin layer chromatography (TLC silica gel 60, Merck). 
Sphinganine, sphingomyelin, ceramide and phosphatidylserine (Avanti Polar 
Lipids) were used as standards. TLC plates were developed with chloroform/
methanol/ammonium hydroxide (65:25:4). [3H]serine-labeled sphinganine 
was quantified using a TLC scanner (radioactivity TLC analyzer RITA, Raytest 
Straubenhardt, Germany); amounts of radiolabeled lipid were determined using 
a [3H]serine calibration curve.
RNA extraction from aortic endothelial cells and VSMC and real-time PCR 
analysis. Endothelial cells and VSMCs were isolated from aortas of NogoA/Bf/f, 
EC-Nogo-A/B-deficient and SMC-Nogo-A/B-deficient mice. Briefly, the aorta 
was dissected and quickly cleaned from surrounding fat tissue. The aorta was 
cannulated and perfused with 400 µl TRIzol for 10 s to isolate endothelial cells. 
The perfusate was collected in a tube and the aorta was snap frozen in liquid 
nitrogen and homogenized in 400 µl TRIzol to isolate VSMCs. Total RNA from 
perfusate and tissue was extracted according to the TRIzol reagent protocol 
(Thermo Scientific). Reverse transcription was then performed using 100 ng 
of RNA and Maxima Reverse Transcriptase (200 U/µl) supplied with 5× buffer 
(250 mM Tris-HCl (pH 8.3 at 25 °C), 375 mM KCl, 15 mM MgCl2, 50 mM DTT; 
Thermo Scientific, USA). The real-time PCR analysis was done with an iCycler 
Applied Biosystems 7700, using SYBR green PCR Master Mix (Qiagen, USA). 
Nogo-B primers were used to evaluate the efficiency of Nogo-B knockdown in 
endothelial cells and VSMCs from EC-Nogo-A/B-deficient and SMC-Nogo-
A/B-deficient mice. VE-cadherin and αSMA primers were used to evaluate the 
purity of the isolated cells. Nogo-B, VE-cadherin and αSMA mRNA levels were 
normalized using the housekeeping gene GAPDH. The following primers were 
used for REAL-TIME PCR: Nogo, forward (GGTGCCTTGTTCAATGGTTT) 
and reverse (ATTCTGCTTTGCGCTTCAAT); VE-cadherin, forward (TAG
CAAGAGTGCGCTGGAGATTCA) and reverse (ACACATCATAGCTGG 
TGGTGTCCA); αSMA, forward (CAGGGAGTAATGGTTGGAAT) and 
reverse (TCTCAAACATAATCTGGGTCA); GAPDH, forward (AGGTCGGTG 
TGAACGGATTTG) and reverse (TGTAGACCATGTAGTTGAGGTCA).
Assessment of Nogo-B expression in aortas from SMC-Nogo-A/B-deficient 
mice. Aortas from Nogo-A/Bf/f and SMC-Nogo-A/B-deficient mice were 
isolated and cleaned from surrounding connective tissue. Endothelial cells from 
the aorta were mechanically removed with a cannula followed by perfusion 
with 1 ml of distilled water to wash out any residual endothelial cells. The 
adventitia was digested with type II collagenase (Worthington 1 mg/ml) 
dissolved in DMEM (20 min, 37 °C), followed by its manual removal. Aortas 
were washed in PBS and snap frozen in liquid nitrogen and homogenized 
in RIPA buffer to perform western blot analysis.
Chronic infusion of AngII. AngII (500 ng/kg/min) was infused using an osmotic 
minipump (model ALZET 2004) (ref. 62). Briefly, minipumps were implanted 
subcutaneously in WT, Nogo-A/B-deficient, NogoA/Bf/f, EC-Nogo-A/B- 
deficient and SMC-Nogo-A/B-deficient male mice at 10 weeks of age. Blood 
pressure was monitored twice per week from day 0 to day 28 of AngII infusion. 
Vascular reactivity was evaluated as described above. In another set of experi-
ments, WT and Nogo-A/B-deficient mice received myriocin (My; 0.3 mg/kg i.p.) 
at day 25, and blood pressure was measured at days 26, 27 and 28. In another set 
of experiments, WT and Nogo-A/B-deficient mice were injected with SEW2187 
(S1P1 agonist, 3 mg/kg i.p., Cayman) or vehicle (DMSO), and blood pressure 
was measured at different time points.
Statistical analysis. Data are expressed as mean ± s.e.m. One-way or two-way 
ANOVA with post hoc Bonferroni’s test was run for all statistical analyses except 
where a Student’s t-test analysis was used. Differences were considered statistically 
significant when P < 0.05. All tests were two-sided. GraphPad Prism software 
(version 5.0, GraphPad Software, San Diego, CA) was used for all statistical 
analysis. The s.d. considered for the calculation was estimated on the basis of 
previous published studies using the tail-cuff system to measure blood pressure 
in mice and by preliminary experiments of vascular reactivity using mesenteric 
arteries from three mice.
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